Abstract: Epidermal growth factor receptortyrosine kinase inhibitors (EGFR-TKIs) are the key to the treatment of advanced nonsmall cell lung cancer (NSCLC), but there are various drugresistant mutations in the latter stage. The first and second generation of EGFRTKIs significantly prolong the survival of patients with EGFR-activated mutant tumors. The third generation of EGFR-TKIs effectively inhibit the progress of T790M mutant tumors. The fourth generation of EGFR-TKIs inhibit both L858R, T790M and L858R, T790M, C797S mutant tumors. Using circulating tumor DNA and exogenous RNA can effectively detect the mutation types of EGFR, and choose EGFR-TKIs therapy or combined chemotherapy according to the mutation types.

Key words: Carcinoma, non-small-cell lung, Receptor, epidermal growth factor, Molecular targeted therapy, Epidermal growth factor receptor-tyrosine kinase inhibitors, Drug resistance